Ipsen’s Dysport Gets Complete Response Letter, Request For REMS
This article was originally published in The Pink Sheet Daily
Executive Summary
Complete response letter issued to Ipsen, requesting a final REMS, label and safety update report for the botulinum toxin product.
You may also be interested in...
Ipsen Confident in U.S. Neurology Push Despite Dysport Delay
Neither FDA’s REMS request nor the prospect of competing with Allergan’s Botox appears to be spoiling Ipsen’s plans to stake a U.S. neurology stronghold.
Ipsen Confident in U.S. Neurology Push Despite Dysport Delay
Neither FDA’s REMS request nor the prospect of competing with Allergan’s Botox appears to be spoiling Ipsen’s plans to stake a U.S. neurology stronghold.
FDA Review Of Ipsen’s Dysport Set Back Three Months
Agency requests a risk communication plan for the cervical dystonia drug candidate.